Findings from the interim analysis showed approximately 9% of patients using Ovaprene experienced a pregnancy. Topline interim data were announced from an ongoing phase 3 trial evaluating Ovaprene ®, ...
SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results